02:20:30 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-22 Ordinarie utdelning CURAS 0.00 DKK
2024-03-21 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-03-31 Ordinarie utdelning CURAS 0.00 DKK
2023-03-30 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-03-25 Ordinarie utdelning CURAS 0.00 DKK
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-01 Extra Bolagsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-03-26 Ordinarie utdelning CURAS 0.00 DKK
2021-03-25 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriMedicinteknik
Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen är bred och har sin huvudsakliga fokus på utveckling av produkter inom området Positron Emissions Tomography (PET). Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.
2022-11-24 07:00:00

Copenhagen, Denmark, 24 November 2022 - Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby publishes the interim report for the period January 1 - September 30, 2022. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Curasight's CEO Ulrich Krasilnikoff comments:

"It has been a busy first nine months of the year for Curasight as we progressed our pipeline of products under our theranostic platform, combining uTRACE[®] diagnostics and uTREAT[®] therapy with the aim of providing improved cancer management.

We believe in `what you see is what you treat' and we therefore were pleased as part of this theranostic approach, to initiate pre-clinical studies testing our uTREAT[®] product in neuroendocrine tumours (NET) and head and neck cancer to add to clinical data we already have from studies with our uTRACE[®] diagnostic product."

Q3 (July - September) 2022
  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -1,602,143 (-807,809) DKK
  • Profit/loss before taxes amounted to -4,504,912 (-1,418,449) DKK
  • Profit/loss for the period amounted to -3,513,832 (-1,106,390) DKK
  • Total assets amounted to 95,748,009 (59,506,515) DKK
  • Equity ratio amounted to 96,2 (94.8) %.
  • Earnings per share amounted to -0,17 (-0.06) DKK
Q1-Q3 (January - September) 2022
  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -4,299,561 (-1,579,771) DKK
  • Profit/loss before taxes amounted to -8,997,274 (-3,495,177) DKK
  • Profit/loss for the period amounted to -7,017,874 (-2,726,238) DKK
  • Total assets amounted to 95,748,009 (59,506,515) DKK
  • Equity ratio amounted to 96,2 (94.8) %.
  • Earnings per share amounted to -0,35 (-0.16) DKK
Highlights during the third quarter
  • On August 25, Ulrich Krasilnikoff and Andreas Kjær presented the company and the Q2 2022 report at HC Andersen Capital.
 
  • On September 4, Curasight announced that the company's CDO Hanne Damgaard Jensen had purchased 7,600 shares at an aggregated volume price of 97,964 DKK on November 1, 2022. Hanne Damgaard Jensen total holdings in Curasight A/S after the purchase of the shares is 35,000 shares.
Highlights after the period
  • On October 13, Curasight announced that it has initiated pre-clinical studies of uPAR targeted radionuclide therapy (uTREAT®) in head and neck cancer and in neuroendocrine tumors (NET). Results are expected to be available during 1H 2023.
  • On November  21, Ulrich Krasilnikoff and Andreas Kjær presented the company and the strategy at SEB Healthcare Seminar 2022.